Financial Snapshot

Revenue
$10.48M
TTM
Gross Margin
79.69%
TTM
Net Earnings
-$37.74M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
184.38%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$15.58M
Q3 2024
Cash
Q3 2024
P/E
-0.3063
Nov 29, 2024 EST
Free Cash Flow
-$21.98M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Revenue $9.761M $11.96M $4.335M $9.390M $5.780M $4.420M $4.360M $140.0K $260.0K $0.00 $0.00
YoY Change -18.36% 175.8% -53.83% 62.46% 30.77% 1.38% 3014.29% -46.15%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Revenue $9.761M $11.96M $4.335M $9.390M $5.780M $4.420M $4.360M $140.0K $260.0K $0.00 $0.00
Cost Of Revenue $2.037M $2.019M $2.333M $3.280M $3.820M $2.770M $880.0K $50.00K $120.0K $1.400M $0.00
Gross Profit $7.724M $9.937M $2.002M $6.110M $1.960M $1.650M $3.480M $90.00K $130.0K -$1.400M $0.00
Gross Profit Margin 79.13% 83.11% 46.18% 65.07% 33.91% 37.33% 79.82% 64.29% 50.0%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Selling, General & Admin $23.05M $26.71M $26.00M $21.00M $20.44M $22.11M $14.33M $6.470M $6.100M $3.680M $450.0K
YoY Change -13.69% 2.72% 23.82% 2.72% -7.55% 54.29% 121.48% 6.07% 65.76% 717.78%
% of Gross Profit 298.39% 268.74% 1298.55% 343.63% 1042.86% 1340.0% 411.78% 7188.89% 4692.31%
Research & Development $18.60M $17.65M $15.08M $6.413M $5.820M $5.150M $4.270M $7.210M $6.480M $2.820M $320.0K
YoY Change 5.38% 17.03% 135.13% 10.19% 13.01% 20.61% -40.78% 11.27% 129.79% 781.25%
% of Gross Profit 240.76% 177.59% 753.2% 104.96% 296.94% 312.12% 122.7% 8011.11% 4984.62%
Depreciation & Amortization $2.013M $1.981M $1.719M $1.727M $1.740M $1.320M $580.0K $50.00K $10.00K
YoY Change 1.62% 15.24% -0.46% -0.75% 31.82% 127.59% 1060.0% 400.0%
% of Gross Profit 26.06% 19.94% 85.86% 28.27% 88.78% 80.0% 16.67% 55.56% 7.69%
Operating Expenses $41.64M $44.35M $41.08M $27.41M $26.25M $27.26M $18.61M $13.68M $12.58M $6.510M $780.0K
YoY Change -6.11% 7.98% 49.86% 4.42% -3.71% 46.48% 36.04% 8.74% 93.24% 734.62%
Operating Profit -$33.92M -$34.42M -$40.71M -$26.65M -$24.29M -$25.61M -$15.13M -$13.59M -$12.45M -$7.910M -$780.0K
YoY Change -1.44% -15.46% 52.77% 9.7% -5.15% 69.27% 11.33% 9.16% 57.4% 914.1%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Interest Expense -$11.51M $12.72M $8.421M $2.792M -$4.720M -$2.300M -$510.0K -$1.030M -$3.820M -$290.0K -$20.00K
YoY Change -190.44% 51.09% 201.61% -159.15% 105.22% 350.98% -50.49% -73.04% 1217.24% 1350.0%
% of Operating Profit
Other Income/Expense, Net $200.0K $950.0K -$765.0K $190.0K $80.00K $320.0K $90.00K -$10.00K -$30.00K
YoY Change -78.95% -224.18% -502.63% 137.5% -75.0% 255.56% -1000.0% -66.67%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Pretax Income -$41.90M -$48.40M -$52.60M -$33.81M -$38.53M -$32.15M -$35.15M -$14.73M -$16.29M -$8.610M -$800.0K
YoY Change -13.42% -7.99% 55.58% -12.25% 19.84% -8.53% 138.63% -9.58% 89.2% 976.25%
Income Tax $0.00 $0.00 $0.00 $0.00 $10.00K $0.00 -$13.18M $0.00 $0.00
% Of Pretax Income
Net Earnings -$41.30M -$48.40M -$52.60M -$33.81M -$38.54M -$32.15M -$21.97M -$14.73M -$16.29M -$8.610M -$800.0K
YoY Change -14.66% -7.99% 55.58% -12.28% 19.88% 46.34% 49.15% -9.58% 89.2% 976.25%
Net Earnings / Revenue -423.11% -404.78% -1213.38% -360.05% -666.78% -727.38% -503.9% -10521.43% -6265.38%
Basic Earnings Per Share -$1.79 -$36.18 -$1.18 -$3.00
Diluted Earnings Per Share -$1.79 -$36.18 -$1.18 -$3.00 -$7.755M -$153.1M -$7.576M -$1.473B -$1.629B -$861.0M -$80.00M

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Cash & Short-Term Investments $6.469M $5.469M $17.05M $8.090M $3.500M $2.570M $520.0K $950.0K $7.700M $850.0K $190.0K
YoY Change 18.28% -67.93% 110.77% 131.14% 36.19% 394.23% -45.26% -87.66% 805.88% 347.37%
Cash & Equivalents $520.0K $950.0K $7.700M $850.0K $190.0K
Short-Term Investments
Other Short-Term Assets $10.12M $7.361M $4.339M $2.360M $2.200M $1.240M $740.0K $1.180M $470.0K $2.500M $100.0K
YoY Change 37.49% 69.65% 83.86% 7.27% 77.42% 67.57% -37.29% 151.06% -81.2% 2400.0%
Inventory $9.189M $7.024M $4.900M $2.780M $2.130M $3.340M $2.070M $410.0K $230.0K $200.0K
Prepaid Expenses
Receivables $1.967M $1.879M $1.709M $4.530M $1.690M $1.000M $470.0K $0.00 $60.00K $0.00
Other Receivables $217.0K $588.0K $435.0K $30.00K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $27.96M $22.32M $28.43M $17.79M $9.520M $8.150M $3.800M $2.560M $8.450M $3.550M $290.0K
YoY Change 25.28% -21.5% 59.83% 86.87% 16.81% 114.47% 48.44% -69.7% 138.03% 1124.14%
Property, Plant & Equipment $1.672M $1.697M $1.734M $680.0K $710.0K $760.0K $1.220M $890.0K $830.0K $870.0K $0.00
YoY Change -1.47% -2.13% 155.0% -4.23% -6.58% -37.7% 37.08% 7.23% -4.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.012M $995.0K $446.0K $40.00K $150.0K $420.0K $0.00 $120.0K $3.120M $0.00
YoY Change 1.71% 123.09% 1015.0% -73.33% -64.29% -100.0% -96.15%
Total Long-Term Assets $22.80M $25.13M $24.83M $25.05M $26.89M $32.89M $39.83M $1.000M $3.960M $870.0K $0.00
YoY Change -9.28% 1.21% -0.87% -6.84% -18.24% -17.42% 3883.0% -74.75% 355.17%
Total Assets $50.76M $47.45M $53.27M $42.84M $36.41M $41.04M $43.63M $3.560M $12.41M $4.420M $290.0K
YoY Change
Accounts Payable $4.974M $5.808M $4.929M $4.760M $5.350M $5.410M $7.350M $520.0K $570.0K $700.0K $10.00K
YoY Change -14.36% 17.83% 3.55% -11.03% -1.11% -26.39% 1313.46% -8.77% -18.57% 6900.0%
Accrued Expenses $4.146M $8.648M $7.357M $4.490M $3.260M $4.940M $2.200M $580.0K $800.0K $1.320M $80.00K
YoY Change -52.06% 17.55% 63.85% 37.73% -34.01% 124.55% 279.31% -27.5% -39.39% 1550.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $4.850M $1.140M $0.00 $0.00 $390.0K $0.00
YoY Change -100.0% 325.44% -100.0%
Long-Term Debt Due $4.867M $15.88M $3.184M $3.790M $6.780M $11.24M $4.280M $2.070M $1.860M $420.0K $520.0K
YoY Change -69.36% 398.84% -15.99% -44.1% -39.68% 162.62% 106.76% 11.29% 342.86% -19.23%
Total Short-Term Liabilities $13.99M $30.34M $15.47M $13.22M $15.39M $26.66M $15.39M $4.190M $3.910M $3.480M $720.0K
YoY Change -53.9% 96.1% 17.03% -14.1% -42.27% 73.23% 267.3% 7.16% 12.36% 383.33%
Long-Term Debt $30.99M $17.74M $25.02M $12.42M $450.0K $0.00 $10.98M $1.820M $4.100M $0.00 $0.00
YoY Change 74.67% -29.09% 101.47% 2660.0% -100.0% 503.3% -55.61%
Other Long-Term Liabilities $886.0K $725.0K $919.0K $0.00 $10.00K $0.00 $1.880M $0.00
YoY Change 22.21% -21.11% -100.0% -100.0%
Total Long-Term Liabilities $31.88M $18.47M $25.94M $12.42M $450.0K $0.00 $10.98M $1.830M $4.100M $1.880M $0.00
YoY Change 72.61% -28.8% 108.86% 2660.0% -100.0% 500.0% -55.37% 118.09%
Total Liabilities $45.80M $48.11M $41.65M $25.64M $15.84M $26.66M $26.37M $6.020M $8.010M $5.350M $720.0K
YoY Change -4.8% 15.5% 62.46% 61.87% -40.59% 1.1% 338.04% -24.84% 49.72% 643.06%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Basic Shares Outstanding 23.07M 1.312M 44.71M 12.88M
Diluted Shares Outstanding 23.07M 1.312M 44.71M 12.88M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $11.561 Million

About Jaguar Health, Inc.

Jaguar Health Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2015-05-13. Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The firm is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. The company operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

Industry: Pharmaceutical Preparations Peers: AYTU BIOPHARMA, INC cbdMD, Inc. PLx Pharma Winddown Corp. Hoth Therapeutics, Inc. JOHNSON & JOHNSON VYNE Therapeutics Inc. Pulmatrix, Inc. Unrivaled Brands, Inc. WEED, INC. Virpax Pharmaceuticals, Inc.